Fenebrutinib cuts relapses and chronic lesion growth in multiple sclerosis
Roche’s fenebrutinib lowered relapses and chronic lesion growth in multiple sclerosis across late-stage trials, with FDA priority review under way.
From stroke to neurodegeneration — the science and its clinical impact.
From stroke to neurodegeneration — the science and its clinical impact.